Seraxis is a biotechnology company that uses proprietary technologies to develop SR-01, a cell replacement therapy. Its pure insulin-producing cells are micro-encapsulated through a proprietary technology that enables the function of human pancreas cells in type-1 diabetes models without the need for immunosuppression.